Streamline Health Solns Q2 Sales $2.90M Miss $3.15M Estimate

Streamline Health Solns (NASDAQ:STRM) reported quarterly sales of $2.90 million which missed the analyst consensus estimate of $3.15 million by 7.94 percent. This is a 0.45 percent increase over sales of $2.89 million

Streamline Health Solns (NASDAQ:STRM) reported quarterly sales of $2.90 million which missed the analyst consensus estimate of $3.15 million by 7.94 percent. This is a 0.45 percent increase over sales of $2.89 million the same period last year.

Total
0
Shares
Related Posts
Read More

Albemarle: Q4 Earnings Insights

Albemarle (NYSE:ALB) reported its Q4 earnings results on Wednesday, February 16, 2022 at 04:15 PM. Here's what investors need to know about the announcement. Earnings Albemarle beat estimated earnings by 2.02%, reporting an EPS of $1.01 versus an estimate of $0.99.

ALB

Read More

Immutep Announced on Thursday, Successful Meeting With the FDA on Eftilagimod Alpha Plus Chemotherapy for the Treatment of Metastatic Breast Cancer

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the results of a positive follow-up Type C meeting with the US Food and Drug Administration (FDA) regarding late-stage clinical development plans for its first-in-class soluble LAG-3 pr

IMMP